Blackstone Life Sciences will co-fund development of Boston Scientific's VITALYST heart pump under a $455 million collaboration announced November 2. VITALYST is a temporary percutaneous transvalvular circulatory support system, a miniature pump for acute myocardial infarction cardiogenic shock. Neither party said how the $455 million splits, and no milestone or royalty terms were disclosed.
Boston Scientific says this is the first time it has co-funded development of one of its own products with the firm. Nicholas Galakatos, global head of Blackstone Life Sciences, said VITALYST has "the potential to improve on the efficacy and safety" of mechanical circulatory support devices now on the market.
The structure is the part worth studying. Outside capital paid for a late-stage device program without an equity sale, and it arrived while Boston Scientific was already carrying a $14.5 billion Penumbra purchase it has pushed into early 2027 and a cyberattack it put at $150 million of lost third quarter sales.